217 related articles for article (PubMed ID: 31710344)
1. US Food and Drug Administration Recommendations on the Use of Surrogate Measures as End Points in New Anti-infective Drug Approvals.
Hey SP; Kesselheim AS; Patel P; Mehrotra P; Powers JH
JAMA Intern Med; 2020 Jan; 180(1):131-138. PubMed ID: 31710344
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020.
Mitra-Majumdar M; Gunter SJ; Kesselheim AS; Brown BL; Joyce KW; Ross M; Pham C; Avorn J; Darrow JJ
JAMA Netw Open; 2022 May; 5(5):e2212454. PubMed ID: 35579897
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.
Downing NS; Aminawung JA; Shah ND; Krumholz HM; Ross JS
JAMA; 2014 Jan 22-29; 311(4):368-77. PubMed ID: 24449315
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.
Gyawali B; Hey SP; Kesselheim AS
JAMA Intern Med; 2019 Jul; 179(7):906-913. PubMed ID: 31135808
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
[TBL] [Abstract][Full Text] [Related]
6. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
Chen EY; Joshi SK; Tran A; Prasad V
JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.
Naci H; Smalley KR; Kesselheim AS
JAMA; 2017 Aug; 318(7):626-636. PubMed ID: 28810023
[TBL] [Abstract][Full Text] [Related]
8. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016.
Moore TJ; Zhang H; Anderson G; Alexander GC
JAMA Intern Med; 2018 Nov; 178(11):1451-1457. PubMed ID: 30264133
[TBL] [Abstract][Full Text] [Related]
9. Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study.
Wallach JD; Ciani O; Pease AM; Gonsalves GS; Krumholz HM; Taylor RS; Ross JS
BMC Med; 2018 Mar; 16(1):45. PubMed ID: 29562926
[TBL] [Abstract][Full Text] [Related]
10. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
[TBL] [Abstract][Full Text] [Related]
11. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.
Pease AM; Krumholz HM; Downing NS; Aminawung JA; Shah ND; Ross JS
BMJ; 2017 May; 357():j1680. PubMed ID: 28468750
[No Abstract] [Full Text] [Related]
12. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
[TBL] [Abstract][Full Text] [Related]
13. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
Chen EY; Raghunathan V; Prasad V
JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822
[TBL] [Abstract][Full Text] [Related]
14. Use of surrogate outcomes in US FDA drug approvals, 2003-2012: a survey.
Yu T; Hsu YJ; Fain KM; Boyd CM; Holbrook JT; Puhan MA
BMJ Open; 2015 Nov; 5(11):e007960. PubMed ID: 26614616
[TBL] [Abstract][Full Text] [Related]
15. End points and United States Food and Drug Administration approval of oncology drugs.
Johnson JR; Williams G; Pazdur R
J Clin Oncol; 2003 Apr; 21(7):1404-11. PubMed ID: 12663734
[TBL] [Abstract][Full Text] [Related]
16. Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration.
Hilal T; Gonzalez-Velez M; Prasad V
JAMA Intern Med; 2020 Aug; 180(8):1108-1115. PubMed ID: 32539071
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
Hilal T; Sonbol MB; Prasad V
JAMA Oncol; 2019 Jun; 5(6):887-892. PubMed ID: 31046071
[TBL] [Abstract][Full Text] [Related]
18. Assessing tumor-related signs and symptoms to support cancer drug approval.
Williams G; Pazdur R; Temple R
J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
[TBL] [Abstract][Full Text] [Related]
19. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.
Wagner J; Marquart J; Ruby J; Lammers A; Mailankody S; Kaestner V; Prasad V
BMJ; 2018 Mar; 360():k668. PubMed ID: 29514787
[TBL] [Abstract][Full Text] [Related]
20. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
